

Gabe S Sonke

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1479922/gabe-s-sonke-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

101
papers

7,721
citations

31
h-index

87
g-index

107
ext. papers

10,146
ext. citations

8.5
avg, IF

5.46
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 101 | Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 2495-2505 | 59.2 | 1061 |
| 100 | Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1738-1748 | 59.2 | 975 |
| 99 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1274-1284 | 21.7 | 913 |
| 98 | Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 230-240 | 59.2 | 627 |
| 97 | Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2465-2472 | 2.2 | 435 |
| 96 | Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 87-97 | 21.7 | 405 |
| 95 | Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1918-27 | 2.2 | 319 |
| 94 | Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs. <i>Cancer Treatment Reviews</i> , 2017 , 52, 91-104 | 14.4 | 272 |
| 93 | Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 514-524 | 59.2 | 251 |
| 92 | Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. <i>Annals of Surgery</i> , 2015 , 261, 378-82 | 7.8 | 229 |
| 91 | Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology, The</i> , 2015 , 16, 1639-50 | 21.7 | 190 |
| 90 | Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4354-4361 | 2.2 | 155 |
| 89 | Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. <i>Journal of Pathology</i> , 2004 , 202, 23-33 | 9.4 | 144 |
| 88 | Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1630-1640 | 21.7 | 113 |
| 87 | Global cancer control: responding to the growing burden, rising costs and inequalities in access. <i>ESMO Open</i> , 2018 , 3, e000285 | 6 | 98 |
| 86 | Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 136, 35-43 | 4.4 | 73 |
| 85 | Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 127-134 | 4.4 | 62 |

| | | | |
|----|---|------|----|
| 84 | Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. <i>International Journal of Cancer</i> , 2019 , 144, 263-272 | 7.5 | 56 |
| 83 | Guiding breast-conserving surgery in patients after neoadjuvant systemic therapy for breast cancer: a comparison of radioactive seed localization with the ROLL technique. <i>Annals of Surgical Oncology</i> , 2013 , 20, 2569-75 | 3.1 | 53 |
| 82 | Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 1363-1364 | 59.2 | 52 |
| 81 | alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. <i>Journal of Urology</i> , 2001 , 165, 38-41 | 2.5 | 51 |
| 80 | Targeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 1190-1200 | 9.7 | 50 |
| 79 | Why do patients choose (not) to participate in an exercise trial during adjuvant chemotherapy for breast cancer?. <i>Psycho-Oncology</i> , 2016 , 25, 964-70 | 3.9 | 46 |
| 78 | Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , 2018 , 167, 659-669 | 4.4 | 45 |
| 77 | Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data. <i>British Journal of Sports Medicine</i> , 2019 , 53, 812 | 10.3 | 43 |
| 76 | Design of the Physical exercise during Adjuvant Chemotherapy Effectiveness Study (PACES): a randomized controlled trial to evaluate effectiveness and cost-effectiveness of physical exercise in improving physical fitness and reducing fatigue. <i>BMC Cancer</i> , 2010 , 10, 673 | 4.8 | 41 |
| 75 | SERPINA6, BEX1, AGTR1, SLC26A3, and LAPT4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 137, 213-234 | 4.4 | 40 |
| 74 | Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. <i>British Journal of Cancer</i> , 2015 , 113, 396-402 | 8.7 | 36 |
| 73 | Poor outcomes of chronic active Epstein-Barr virus infection and hemophagocytic lymphohistiocytosis in non-Japanese adult patients. <i>Clinical Infectious Diseases</i> , 2008 , 47, 105-8 | 11.6 | 36 |
| 72 | Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2107-14 | 2.2 | 34 |
| 71 | Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer. <i>British Journal of Cancer</i> , 2018 , 119, 408-418 | 8.7 | 31 |
| 70 | Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 627-36 | 4.4 | 30 |
| 69 | Prenatal and perinatal risk factors and testicular cancer: a hospital-based case-control study. <i>Oncology Research</i> , 2007 , 16, 383-7 | 4.8 | 29 |
| 68 | The facilitating role of chemotherapy in the palliative phase of cancer: qualitative interviews with advanced cancer patients. <i>PLoS ONE</i> , 2013 , 8, e77959 | 3.7 | 29 |
| 67 | Variability of pressure-flow studies in men with lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2000 , 19, 637-51; discussion 651-6 | 2.3 | 28 |

| | | | |
|----|--|------|----|
| 66 | Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. <i>Drugs</i> , 2017 , 77, 1313-1336 | 12.1 | 25 |
| 65 | Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2041-2050 | 2.2 | 25 |
| 64 | Cost-utility and cost-effectiveness of physical exercise during adjuvant chemotherapy. <i>European Journal of Health Economics</i> , 2018 , 19, 893-904 | 3.6 | 24 |
| 63 | Effectiveness of chemotherapy in measurable granulosa cell tumors: a retrospective study and review of literature. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, 496-505 | 3.5 | 24 |
| 62 | HIGH ENERGY TRANSURETHRAL MICROWAVE THERMOTHERAPY FOR THE TREATMENT OF PATIENTS IN URINARY RETENTION. <i>Journal of Urology</i> , 2000 , 163, 1457-1460 | 2.5 | 24 |
| 61 | Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 888-892 | 3.5 | 23 |
| 60 | PREDICTION OF BLADDER OUTLET OBSTRUCTION IN MEN WITH LOWER URINARY TRACT SYMPTOMS USING ARTIFICIAL NEURAL NETWORKS. <i>Journal of Urology</i> , 2000 , 163, 300-305 | 2.5 | 23 |
| 59 | Low reproducibility of maximum urinary flow rate determined by portable flowmetry. <i>Neurourology and Urodynamics</i> , 1999 , 18, 183-91 | 2.3 | 23 |
| 58 | MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2017 , 164, 99-106 | 4.4 | 22 |
| 57 | Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. <i>Breast</i> , 2016 , 29, 153-9 | 3.6 | 22 |
| 56 | Proliferative activity and branching morphogenesis in the human prostate: a closer look at pre- and postnatal prostate growth. <i>Prostate</i> , 2001 , 49, 132-9 | 4.2 | 21 |
| 55 | Moderators of Exercise Effects on Cancer-related Fatigue: A Meta-analysis of Individual Patient Data. <i>Medicine and Science in Sports and Exercise</i> , 2020 , 52, 303-314 | 1.2 | 20 |
| 54 | The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 361-71 | 4.4 | 19 |
| 53 | Recruitment to and pilot results of the PACES randomized trial of physical exercise during adjuvant chemotherapy for colon cancer. <i>International Journal of Colorectal Disease</i> , 2018 , 33, 29-40 | 3 | 19 |
| 52 | Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial. <i>BMC Cancer</i> , 2018 , 18, 1146 | 4.8 | 19 |
| 51 | Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 112, 198-207 | 7 | 18 |
| 50 | Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.. <i>New England Journal of Medicine</i> , 2022 , 386, 942-950 | 59.2 | 18 |
| 49 | Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval. <i>PLoS ONE</i> , 2015 , 10, e0120832 | 3.7 | 17 |

| | | | |
|----|--|------|----|
| 48 | Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study. <i>European Journal of Cancer</i> , 2017 , 74, 47-54 | 7.5 | 16 |
| 47 | Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.. <i>Lancet Oncology</i> , 2021 , | 21.7 | 16 |
| 46 | Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer. <i>Obstetrics and Gynecology International</i> , 2015 , 2015, 464123 | 2 | 15 |
| 45 | Intra- and inter-investigator variation in the analysis of pressure-flow studies in men with lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2000 , 19, 221-32 | 2.3 | 15 |
| 44 | Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes. <i>PLoS ONE</i> , 2017 , 12, e0176782 | 3.7 | 14 |
| 43 | Heart failure after treatment for breast cancer. <i>European Journal of Heart Failure</i> , 2020 , 22, 366-374 | 12.3 | 14 |
| 42 | Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on. <i>Cancer</i> , 2019 , 125 Suppl 24, 4587-4593 | 6.4 | 14 |
| 41 | A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. <i>Trials</i> , 2017 , 18, 202 | 2.8 | 12 |
| 40 | High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 528-534 | 13.4 | 11 |
| 39 | Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer. <i>Breast Journal</i> , 2013 , 19, 419-26 | 1.2 | 11 |
| 38 | Myocardial dysfunction in long-term breast cancer survivors treated at ages 40-50 years. <i>European Journal of Heart Failure</i> , 2020 , 22, 338-346 | 12.3 | 11 |
| 37 | Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery. <i>Gynecologic Oncology</i> , 2018 , 148, 56-61 | 4.9 | 11 |
| 36 | A philosophical perspective supports the need for patient-outcome studies in diagnostic test evaluation. <i>Journal of Clinical Epidemiology</i> , 2009 , 62, 58-61 | 5.7 | 10 |
| 35 | A method for estimating within-patient variability in maximal urinary flow rate adjusted for voided volume. <i>Urology</i> , 2002 , 59, 368-72 | 1.6 | 10 |
| 34 | Prognostic factors in patients with oligometastatic breast cancer - A systematic review. <i>Cancer Treatment Reviews</i> , 2020 , 91, 102114 | 14.4 | 9 |
| 33 | Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore. <i>Clinical Cancer Research</i> , 2019 , 25, 4985-4992 | 12.9 | 8 |
| 32 | Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study. <i>Breast Cancer Research and Treatment</i> , 2021 , 185, 205-214 | 4.4 | 8 |
| 31 | Adjuvant chemotherapy in small node-negative triple-negative breast cancer. <i>European Journal of Cancer</i> , 2020 , 135, 66-74 | 7.5 | 7 |

| | | | |
|----|--|-----|---|
| 30 | Long-term prognosis of young breast cancer patients (40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. <i>BMJ Open</i> , 2017 , 7, e017842 | 3 | 7 |
| 29 | Bereaved relatives' experiences during the incurable phase of cancer: a qualitative interview study. <i>BMJ Open</i> , 2015 , 5, e009009 | 3 | 7 |
| 28 | Additional value of F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer. <i>Cancer Imaging</i> , 2017 , 17, 15 | 5.6 | 5 |
| 27 | Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkab010 | 4.6 | 5 |
| 26 | Complex challenges for patients with protracted incurable cancer: an ethnographic study in a comprehensive cancer centre in the Netherlands. <i>BMJ Open</i> , 2019 , 9, e024450 | 3 | 3 |
| 25 | Prognosis of acute coronary syndromes after radiotherapy for breast cancer. <i>Radiotherapy and Oncology</i> , 2020 , 146, 110-117 | 5.3 | 3 |
| 24 | Enrichment of high-grade tumors in breast cancer gene expression studies. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 327-335 | 4.4 | 3 |
| 23 | Optimising end of life care requires an individualised approach. <i>BMJ, The</i> , 2014 , 348, g2312 | 5.9 | 3 |
| 22 | A philosophical approach to diagnostic test evaluation. <i>Annals of Internal Medicine</i> , 2007 , 146, 757; author reply 757-8 | 8 | 3 |
| 21 | Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?. <i>Cureus</i> , 2015 , 7, e433 | 1.2 | 3 |
| 20 | Diagnostic research in benign prostatic hyperplasia--from sensitivity to neural networks. <i>Current Opinion in Urology</i> , 1999 , 9, 31-7 | 2.8 | 3 |
| 19 | Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. <i>European Journal of Cancer</i> , 2020 , 139, 59-67 | 7.5 | 3 |
| 18 | Ribociclib plus fulvestrant in the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 93-106 | 3.5 | 3 |
| 17 | Validation of the online prediction model CancerMath in the Dutch breast cancer population. <i>Breast Cancer Research and Treatment</i> , 2019 , 178, 665-681 | 4.4 | 2 |
| 16 | Doctors' reports about palliative systemic treatment: A medical record study. <i>Palliative Medicine</i> , 2017 , 31, 239-246 | 5.5 | 2 |
| 15 | Analytical and pharmacological consequences of the in vivo deamidation of trastuzumab and pertuzumab.. <i>Analytical and Bioanalytical Chemistry</i> , 2022 , 414, 1513-1524 | 4.4 | 2 |
| 14 | Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1928-1934 | 3.5 | 2 |
| 13 | Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1506-1514 | 9.7 | 2 |

| | | | |
|----|--|------|---|
| 12 | Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review. <i>JAMA Oncology</i> , 2021 , 7, 1231-1238 | 13.4 | 2 |
| 11 | Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101536 | 2.2 | 2 |
| 10 | Herkennen van inflammatoir mammacarcinoom. <i>Huisarts En Wetenschap</i> , 2017 , 60, 404-406 | 0.1 | 1 |
| 9 | Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.. <i>Journal of the National Cancer Institute</i> , 2022 , | 9.7 | 1 |
| 8 | Socioeconomic status and its relation with breast cancer recurrence and survival in young women in the Netherlands.. <i>Cancer Epidemiology</i> , 2022 , 77, 102118 | 2.8 | 1 |
| 7 | Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2021 , 78, 86-86 | 4.6 | 1 |
| 6 | Improved risk estimation of locoregional recurrence, secondary contralateral tumors and distant metastases in early breast cancer: the INFLUENCE 2.0 model. <i>Breast Cancer Research and Treatment</i> , 2021 , 189, 817-826 | 4.4 | 1 |
| 5 | Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance.. <i>Npj Breast Cancer</i> , 2022 , 8, 60 | 7.8 | 1 |
| 4 | Applying Risk-Based Follow-Up Strategies on the Dutch Breast Cancer Population: Consequences for Care and Costs. <i>Value in Health</i> , 2020 , 23, 1149-1156 | 3.3 | 0 |
| 3 | Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 185, 817-830 | 4.4 | 0 |
| 2 | Standardizing HIPEC and perioperative care for patients with ovarian cancer in the Netherlands using a Delphi-based consensus.. <i>Gynecologic Oncology Reports</i> , 2022 , 39, 100945 | 1.3 | 0 |
| 1 | Lower pre-hospital case fatality after myocardial infarction creates a survival benefit for women compared with men. <i>American Journal of Cardiology</i> , 2007 , 99, 1481 | 3 | |